The telehealth company’s meteoric rise has hit a roadblock after FDA regulations challenge its weight-loss drug business, setting up a crucial test for the stock ahead of Monday’s earnings report. 原文链接：Read More 文章导航 Trump FTC Chair Pledges to Keep Aggressive Merger Enforcement The Value of London Fashion Week